SAN DIEGO, July 27, 2010 (GLOBE NEWSWIRE) -- Entest BioMedical Inc. (OTCBB:ENTB) today announced that it has retained Crescendo Communications, LLC ("Crescendo") as its investor relations firm to help broaden awareness of the company within the financial markets.
"The team at Crescendo has unique expertise within the biotech and pharmaceutical sectors, as well as a successful track record advising small cap public companies. Crescendo has also been an innovator with new communications services and technologies such as www.InvestorRoadshow.com," said David Koos, Chairman and CEO of Entest BioMedical, Inc. "We are confident that Crescendo will help us more proactively communicate our business model and the important steps we are taking to become a leading player in the veterinary medicine market."
"We are impressed with the platform Entest had built within the veterinary medicine market. The company's innovative medical therapies, including ImenVax™ and ENT‐576™, address sizeable and underserved markets. Additionally, their veterinary focus offers a faster and less costly path to commercialization than human therapies. The company has developed a unique plan to generate near-term revenue and sustainable cash flow by consolidating profitable independent veterinary clinics acquired at low market multiples that should allow them to self-fund their R&D while simultaneously providing a platform for clinical trials and marketing of their products," said David Waldman, President of Crescendo. "We are pleased to represent Entest BioMedical and look forward to launching a comprehensive investor communications program."
About Entest BioMedical (www.entestbio.com)
Entest BioMedical is a developer of veterinary medicines that harness the animal's own reparative/immunological mechanisms. The company's products include immunotherapeutic cancer vaccines for canines (ImenVax™ I, II & III) and a stem cell therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in thoroughbred race horses (ENT‐576™). The company's Immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. The immuno-therapeutic cancer vaccine utilizes the animals own cancer cells in order to induce an immune response. The company's proprietary ENT‐576™ program for COPD incorporates "homing" stimulator technology that directs stem cells to diseased lung tissue. This approach could cause damaged tissue to regenerate with potential to alleviate symptoms and reverse lung damage.
About Crescendo Communications, LLC (www.crescendo-ir.com)
Crescendo Communications, LLC, headquartered in New York City, is an emerging leader within the investor relations industry. The principals of Crescendo have represented hundreds of companies across all market caps and industries. The firm was founded on a strategic and professional approach to investor relations that builds awareness of public companies through tailored outreach programs that target institutional investors, analysts, and the financial media. Crescendo's approach is centered around properly educating investors and cultivating trust between the firm's clients and the Wall Street community.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.